BS_4FZS7TX4
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- overall_survival_months
- 82.80000000000001
- os_event
- false
- age_years
- 3.351
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -6.477590979
- umap2_2d
- 0.312772683
- umap1_3d
- 0.924852272
- umap2_3d
- 3.915630901
- umap3_3d
- 0.211250145
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.440
- PROTEIN_SECRETION+0.400
- ADIPOGENESIS+0.390
- BILE_ACID_METABOLISM+0.370
- HEME_METABOLISM+0.320
- UV_RESPONSE_DN+0.300
- FATTY_ACID_METABOLISM+0.280
- PEROXISOME+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- CHOLESTEROL_HOMEOSTASIS+0.240
Top 10 suppressed
- E2F_TARGETS-0.430
- PANCREAS_BETA_CELLS-0.420
- MYC_TARGETS_V2-0.400
- G2M_CHECKPOINT-0.370
- ALLOGRAFT_REJECTION-0.250
- TNFA_SIGNALING_VIA_NFKB-0.230
- INTERFERON_ALPHA_RESPONSE-0.200
- INFLAMMATORY_RESPONSE-0.180
- INTERFERON_GAMMA_RESPONSE-0.160
- ANGIOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4FZS7TX4 | Ependymoma NOS | — | 0.909 |
| 2 | SJEPD030908_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.736 |
| 3 | BS_SDA4RMMG | pilocytic astrocytoma | — | 0.732 |
| 4 | TCGA-44-8120-01A-11R-2241-07 | — | cohortA1 | 0.727 |
| 5 | BS_17WYVEEC | pilocytic astrocytoma | — | 0.723 |
| 6 | BS_Y0PCBNJV | pilocytic astrocytoma | — | 0.722 |
| 7 | BS_RWJZFTP9 | low-grade glioma | — | 0.719 |
| 8 | BS_66HQ3E4Z | pilocytic astrocytoma | — | 0.718 |
| 9 | TCGA-A2-A0EM-01A-11R-A034-07 | — | B | 0.715 |
| 10 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.713 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.390 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.320 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |